TIDMAREC

RNS Number : 3281V

Arecor Therapeutics PLC

09 August 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

ARECOR GRANTED EUROPEAN PATENTS PROTECTING PROPRIETARY FORMULATIONS OF

HIGH CONCENTRATION HUMIRA(R) BIOSIMILAR

- Patents demonstrate strength of innovative Arestat(TM) technology and its potential in development of enhanced formulations of high value biologics

- Further strengthens Group's extensive patent portfolio protecting its proprietary Arestat(TM) technology and proprietary products

Cambridge, UK, 9 August 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, is pleased to announce that the European Patent Office has granted two patents ( EP3592383B1 and EP3592385B1) protecting the Group's novel formulations of high-concentration adalimumab until 2038.

Adalimumab, sold by AbbVie under the brand name Humira (R) , has been a blockbuster monoclonal antibody product since its launch in 2003, indicated for a number of inflammatory diseases such as rheumatoid arthritis and Crohn's disease. Global sales of Humira increased by 4% in 2021 with total sales reported as $21bn(1) . Several biosimilar versions of adalimumab have also entered the European market since 2018 and are due to be launched in the US in 2023.

Humira (R) was originally approved as a 50 mg/mL adalimumab product comprising citrate as a key formulation ingredient. An improved product was subsequently launched by AbbVie with a high adalimumab concentration (100 mg/mL) in the absence of citrate, resulting in less injection site-related pain and providing greater patient convenience due to the lower injection volumes. The market for high-concentration adalimumab has been steadily increasing both in the US and in Europe with high-concentration adalimumab now representing about 80% of the total US market(2) .

Formulating a high concentration version of adalimumab is technically challenging and further complicated by a complex patent landscape surrounding adalimumab formulations. Using its proprietary Arestat (TM) technology, Arecor has developed novel formulations enabling a high-concentration adalimumab product (100 mg/mL or higher) with excellent stability. The two granted European patents protect the novel design space enabling these formulations. Corresponding patents in the US are expected to be granted later in 2022.

Sarah Howell, CEO of Arecor, commented : "These European patents for high-concentration adalimumab are an important addition to Arecor's product patent portfolio and provide further proof of the potential of our Arestat(TM) technology in the development of enhanced biologic products, including high value biosimilars.

"We have been very successful in applying the technology platform to develop enhanced versions of existing products with key enabling features, within our own In-house portfolio of proprietary products and with leading healthcare companies through our technology partnerships. The biologics field is one in which we have considerable experience, as demonstrated by the novel and differentiated formulation of AT220, a separate biosimilar product in our current partnered programmes, formulated by Arecor and licensed to one of our global pharmaceutical partners, which is now in late-stage development."

Arecor has invested in building a strong patent portfolio to protect the Arestat(TM) technology platform and its proprietary pipeline products. The Group's intellectual property (IP) portfolio currently comprises 36 patent families, including >50 granted patents in Europe, the US and in other key territories. As part of this strategy, Arecor has been developing robust IP directed to the novel compositions of differentiated therapeutic products that offer greater convenience of use for patients or healthcare professionals. EP3592383B1 and EP3592385B1 represent a growing number of the Group's patents in this area.

   1.     AbbVie Form 10-K 2021 p41 

2. https://www.centerforbiosimilars.com/view/samsung-bioepis-and-organiz-seek-to-enter-the-market-for-high-concentration-adalimumab

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc                    www.arecor.com 
 Dr Sarah Howell, Chief Executive Officer   Tel: +44 (0) 1223 426060 
                                             Email: info@arecor.com 
 
 Susan Lowther, Chief Financial Officer     Tel: +44 (0) 1223 426060 
                                             Email: info@arecor.com 
 
 Mo Noonan, Communications                  Tel: +44 (0) 7876 444977 
                                             Email: mo.noonan@arecor.com 
 
 Panmure Gordon (UK) Limited (NOMAD         Tel: +44 (0) 20 7886 2500 
  and Broker) 
  Freddy Crossley, Emma Earl (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications 
 Chris Gardner, David Daley, Angela         Tel: +44 (0) 20 3709 5700 
  Gray                                       Email: arecor@consilium-comms.com 
 

Notes to Editors

About Arestat(TM)

Arecor's Arestat(TM) technology enables superior product profiles across a broad range of therapies, including various types of biopharmaceuticals and specialty hospital products. In addition to its internal portfolio of superior proprietary products in diabetes and other indications, Arecor leverages the Arestat(TM) technology in partnerships with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products under a technology licensing model .

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM) , we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat (TM) platform is supported by an extensive patent portfolio .

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUWVRRUKUWRUR

(END) Dow Jones Newswires

August 09, 2022 02:00 ET (06:00 GMT)

Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Arecor Therapeutics Charts.
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Arecor Therapeutics Charts.